Cargando…

Anti B cell targeted therapy for autoimmune hemolytic anemia in an infant

Autoimmune hemolytic anemia (AIHA) is an immune mediated destruction of erythrocytes, which has a good prognosis in children. It is known to have chronic, remitting or relapsing course, especially in infants and adolescents. Treatment of refractory or relapsing AIHA is a challenge as the other aim o...

Descripción completa

Detalles Bibliográficos
Autores principales: Makadia, Darshak, Siddaiahgari, Sirisha Rani, Latha, M. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3793529/
https://www.ncbi.nlm.nih.gov/pubmed/24130393
http://dx.doi.org/10.4103/0253-7613.117755
_version_ 1782477833187098624
author Makadia, Darshak
Siddaiahgari, Sirisha Rani
Latha, M. S.
author_facet Makadia, Darshak
Siddaiahgari, Sirisha Rani
Latha, M. S.
author_sort Makadia, Darshak
collection PubMed
description Autoimmune hemolytic anemia (AIHA) is an immune mediated destruction of erythrocytes, which has a good prognosis in children. It is known to have chronic, remitting or relapsing course, especially in infants and adolescents. Treatment of refractory or relapsing AIHA is a challenge as the other aim of the treatment is to avoid prolonged exposure to steroids or other immunosuppressants in small children. Rituximab is used in patients who are non-responsive to conventional treatment such as steroids, intravenous immunoglobulins and transfusion therapy. It has varying therapeutic success rate. We report a case of AIHA in a 4-month-old infant who had ill-sustained response to conventional therapy, but responded to rituximab.
format Online
Article
Text
id pubmed-3793529
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-37935292013-10-15 Anti B cell targeted therapy for autoimmune hemolytic anemia in an infant Makadia, Darshak Siddaiahgari, Sirisha Rani Latha, M. S. Indian J Pharmacol Drug Watch Autoimmune hemolytic anemia (AIHA) is an immune mediated destruction of erythrocytes, which has a good prognosis in children. It is known to have chronic, remitting or relapsing course, especially in infants and adolescents. Treatment of refractory or relapsing AIHA is a challenge as the other aim of the treatment is to avoid prolonged exposure to steroids or other immunosuppressants in small children. Rituximab is used in patients who are non-responsive to conventional treatment such as steroids, intravenous immunoglobulins and transfusion therapy. It has varying therapeutic success rate. We report a case of AIHA in a 4-month-old infant who had ill-sustained response to conventional therapy, but responded to rituximab. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3793529/ /pubmed/24130393 http://dx.doi.org/10.4103/0253-7613.117755 Text en Copyright: © Indian Journal of Pharmacology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Drug Watch
Makadia, Darshak
Siddaiahgari, Sirisha Rani
Latha, M. S.
Anti B cell targeted therapy for autoimmune hemolytic anemia in an infant
title Anti B cell targeted therapy for autoimmune hemolytic anemia in an infant
title_full Anti B cell targeted therapy for autoimmune hemolytic anemia in an infant
title_fullStr Anti B cell targeted therapy for autoimmune hemolytic anemia in an infant
title_full_unstemmed Anti B cell targeted therapy for autoimmune hemolytic anemia in an infant
title_short Anti B cell targeted therapy for autoimmune hemolytic anemia in an infant
title_sort anti b cell targeted therapy for autoimmune hemolytic anemia in an infant
topic Drug Watch
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3793529/
https://www.ncbi.nlm.nih.gov/pubmed/24130393
http://dx.doi.org/10.4103/0253-7613.117755
work_keys_str_mv AT makadiadarshak antibcelltargetedtherapyforautoimmunehemolyticanemiainaninfant
AT siddaiahgarisirisharani antibcelltargetedtherapyforautoimmunehemolyticanemiainaninfant
AT lathams antibcelltargetedtherapyforautoimmunehemolyticanemiainaninfant